The unique features of TIGR® Matrix Surgical Mesh have been recognized with the first U.S. patent now granted.
The patent relates to a resorbable polymeric mesh implant with an interlocking knitted structure comprising two or more sets of fibers with different times of degradation, allowing a stepwise increase in the relative distension of the overall mesh over time, intended to be used in the reconstruction of soft tissue defects where weakness exists.
Roger Johansson (Ph.D) – Vice President Sweden said: ”We believe that these patented features, which allow gradually increasing compliance, are unique and central to the physiological design concept at the core of TIGR® Matrix. Along with the positive study results to date, this provides the necessary encouragement to move ahead with our broader clinical research program.”
TIGR® Matrix Surgical Mesh is the World’s 1st Long-Term Resorbable, (100% Absorbable) Synthetic Mesh indicated for reinforcement of soft tissue where weakness exists. Its unique patented dual-fiber construction is designed for gradually increasing mechanical compliance, making it strong for 6 months and gone in 3 years. The US Food and Drug Administration (FDA) gave the company 510(k) clearance to market TIGR® Matrix Surgical Mesh in February 2010. In August 2011 Novus Scientific received CE Mark approval from BSI for TIGR® Matrix Surgical Mesh in Europe.
TIGR® Matrix Surgical Mesh is available for sale in the U.S. and Europe.
About Novus Scientific
Novus Scientific (www.novusscientific.com) is an innovator in the development and commercialization of resorbable synthetic medical devices.
For comprehensive information vist our PRESSROOM: http://www.mynewsdesk.com/pressroom/novus-scientific
TIGR® is a trademark of Novus Scientific Pte. Ltd
CONTACT:
Roger Johansson: +46 (0)73 396 55 45- roger.johansson@novusscientific.com
